No Data
No Data
Kintara Therapeutics Eyes Acquisition Amidst Cautionary Advice
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
Express News | Kintara Therapeutics Inc - Under Terms of Agreement, Tuhura Will Pay Kineta $5.0 Mln
Express News | Tuhura Biosciences Enters Into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s Kva12123 Novel Anti-Vista Checkpoint Inhibitor
Kintara Therapeutics Outlines Progress and Potential Risks
Express News | Kintara Therapeutics and Tuhura Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
No Data
james beets : What's the RS do we know? is it 4-1
I only have 19k shares. haven't decided if Imma hold it through the merger or not or just take my profit and be happy.
Youngbuffet OP james beets : follow whatever pays you, not under must you hold through merger. But as for me, is a long thing for me till I hit my PT